论文部分内容阅读
目的探讨β联蛋白、淋巴样增强因子1在恶性黑素瘤中的表达及意义。方法采用免疫组化PowerVisionTM二步法检测25例皮内痣、45例恶性黑素瘤中β联蛋白、淋巴样增强因子1的表达情况。结果β联蛋白在恶性黑素瘤中异常表达率为73％,皮内痣为36％,两组差异有统计学意义;淋巴样增强因子1在恶性黑素瘤中阳性表达率为62．2％,皮内痣组为0,两组差异有统计学意义。肿瘤组织中淋巴样增强因子1高表达率与淋巴结转移、TNM分期密切相关(P<0．05),而β联蛋白异常表达率与淋巴结转移及TNM分期无明显关系;β联蛋白异常表达与淋巴样增强因子1高表达之间存在正相关 (P<0．05)。结论β联蛋白、淋巴样增强因子1异常表达可能与恶性黑素瘤发病相关。
Objective To investigate the expression and significance of β-catenin and lymphoid augmentation factor 1 in malignant melanoma. Methods The expression of β-catenin and lymphoid enhancement factor 1 in 25 cases of intradermal nevus and 45 cases of malignant melanoma was detected by immunohistochemistry PowerVisionTM two-step method. Results The abnormal expression rate of β-catenin was 73% in malignant melanoma and 36% in intradermal nevus. The difference between the two groups was statistically significant. The positive expression rate of lymphoid augmentation factor 1 in malignant melanoma was 62.2%. %, the skin nevus group was 0, the difference between the two groups was statistically significant. The high expression rate of lymphoid augmentation factor 1 in tumor tissues was closely related to lymph node metastasis and TNM stage (P<0.05), but the abnormal expression rate of β-catenin was not significantly related to lymph node metastasis and TNM stage; abnormal expression of β-catenin was associated with There was a positive correlation between high expression of lymphoid enhancing factor 1 (P<0.05). Conclusion The abnormal expression of beta-catenin and lymphoid enhanced factor 1 may be related to the pathogenesis of malignant melanoma.